APP and Alzheimer disease: It was found that in 10‐month‐old female APP/PS1 mice, compared with the noncerebral vasculature targeting formulation RL, RAP‐RL more efficiently rescued the cognitive deficits of AD model mice at a very low dose (0.34 mg kg−1 DMPC).